11/14
07:22 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was downgraded by analysts at Raymond James Financial, Inc. from a "strong-buy" rating to an "outperform" rating.
High
Report
Monopar Therapeutics (NASDAQ:MNPR) was downgraded by analysts at Raymond James Financial, Inc. from a "strong-buy" rating to an "outperform" rating.
11/14
06:52 am
mnpr
Rating for MNPR
High
Report
Rating for MNPR
11/14
06:52 am
mnpr
Rating for MNPR
High
Report
Rating for MNPR
11/14
06:05 am
mnpr
Monopar downgraded to Outperform from Strong Buy at Raymond James
High
Report
Monopar downgraded to Outperform from Strong Buy at Raymond James
11/14
06:05 am
mnpr
Monopar downgraded to Outperform from Strong Buy at Raymond James
High
Report
Monopar downgraded to Outperform from Strong Buy at Raymond James
11/13
04:14 pm
mnpr
Rating for MNPR
High
Report
Rating for MNPR
10/14
07:59 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
10/13
08:04 am
mnpr
Rating for MNPR
High
Report
Rating for MNPR
10/13
08:04 am
mnpr
Rating for MNPR
High
Report
Rating for MNPR
10/13
05:25 am
mnpr
Monopar Therapeutics initiated with an Overweight at Barclays
High
Report
Monopar Therapeutics initiated with an Overweight at Barclays
10/13
05:25 am
mnpr
Monopar Therapeutics initiated with an Overweight at Barclays
High
Report
Monopar Therapeutics initiated with an Overweight at Barclays
10/6
12:58 pm
mnpr
Rating for MNPR
Low
Report
Rating for MNPR
10/6
12:58 pm
mnpr
Rating for MNPR
Low
Report
Rating for MNPR
10/2
09:28 am
mnpr
Rating for MNPR
Medium
Report
Rating for MNPR
10/2
09:28 am
mnpr
Rating for MNPR
Medium
Report
Rating for MNPR
9/25
10:17 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
9/25
07:55 am
mnpr
Rating for MNPR
Medium
Report
Rating for MNPR
9/25
07:49 am
mnpr
Rating for MNPR
Medium
Report
Rating for MNPR
9/25
07:39 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Lake Street Capital to a "strong-buy" rating.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Lake Street Capital to a "strong-buy" rating.
9/23
10:36 am
mnpr
Rating for MNPR
Medium
Report
Rating for MNPR
9/23
10:36 am
mnpr
Rating for MNPR
Medium
Report
Rating for MNPR
9/23
08:46 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) is now covered by analysts at Lake Street Capital. They set a "buy" rating on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) is now covered by analysts at Lake Street Capital. They set a "buy" rating on the stock.
9/23
07:51 am
mnpr
Monopar Therapeutics initiated with a Buy at Lake Street
Medium
Report
Monopar Therapeutics initiated with a Buy at Lake Street
9/23
07:51 am
mnpr
Monopar Therapeutics initiated with a Buy at Lake Street
Medium
Report
Monopar Therapeutics initiated with a Buy at Lake Street
9/16
08:07 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.